Citations are updated once a week. Recently added citations may not appear.
The suggestion is based on each study and bacteria having different weight based on a multitude of factors. For example, how severe a shift is seen.
| Context | Citation |
|---|---|
| Increases Bifidobacterium pseudolongum - : rifaximin |
👶
Review article: the antimicrobial effects of rifaximin on the gut microbiota. Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther ) Vol: 43 Suppl 1 Issue Pages: 3-10 Pub: 2016 Jan Epub: Authors DuPont HL , Publication |
| Increases Bifidobacterium pseudolongum - : rifaximin |
👶
Rifaximin modulates the colonic microbiota of patients with Crohn`s disease: an in vitro approach using a continuous culture colonic model system. The Journal of antimicrobial chemotherapy (J Antimicrob Chemother ) Vol: 65 Issue 12 Pages: 2556-65 Pub: 2010 Dec Epub: 2010 Sep 18 Authors Maccaferri S , Vitali B , Klinder A , Kolida S , Ndagijimana M , Laghi L , Calanni F , Brigidi P , Gibson GR , Costabile A , Publication |
| Increases Bifidobacterium pseudolongum - : rifaximin |
👶
Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacological research (Pharmacol Res ) Vol: 159 Issue Pages: 104936 Pub: 2020 Sep Epub: 2020 May 26 Authors Li Y , Hong G , Yang M , Li G , Jin Y , Xiong H , Qian W , Hou X , Publication |
| Decreases Bifidobacterium pseudolongum - : rifaximin |
📓
Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites. Nutrients (Nutrients ) Vol: 15 Issue 21 Pages: Pub: 2023 Oct 24 Epub: 2023 Oct 24 Authors Luo M , Xie P , Deng X , Fan J , Xiong L , Html Article Publication |
| 0 😁 | 😢 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
